{"id":38657,"date":"2026-03-25T15:46:10","date_gmt":"2026-03-25T15:46:10","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/38657\/"},"modified":"2026-03-25T15:46:10","modified_gmt":"2026-03-25T15:46:10","slug":"roche-launches-respiratory-pathogen-panel-with-flexible-syndromic-testing-for-ce-markets","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/38657\/","title":{"rendered":"Roche Launches Respiratory Pathogen Panel With Flexible Syndromic Testing for CE Markets"},"content":{"rendered":"<p class=\"has-text-align-left\"><a class=\"text-editor-link-class\" href=\"https:\/\/clpmag.com\/diagnostic-technologies\/mass-spectrometry\/roche-mass-spectrometry-steroid-assays-fda-moderate-complexity\/\" rel=\"nofollow noopener\" target=\"_blank\">Roche<\/a> has launched the cobas eplex respiratory pathogen panel 3 (RP3), a qualitative in vitro diagnostic test capable of simultaneously detecting and differentiating up to 25 viral and bacterial targets associated with <a class=\"text-editor-link-class\" href=\"https:\/\/clpmag.com\/disease-states\/infectious-diseases\/flu-respiratory-infections\/labs-stay-respiratory-season\/\" rel=\"nofollow noopener\" target=\"_blank\">respiratory illness<\/a>. The test is now available in countries accepting the <a class=\"text-editor-link-class\" href=\"https:\/\/clpmag.com\/disease-states\/dementias-alzheimer\/roche-elecsys-apoe4-blood-test-ce-mark-alzheimers\/\" rel=\"nofollow noopener\" target=\"_blank\">CE mark<\/a>.<\/p>\n<p class=\"has-text-align-left\">Differential diagnosis of respiratory infections presents a persistent clinical challenge, as many pathogens produce overlapping symptoms. For vulnerable populations\u2014including the elderly, young children, and immunocompromised patients\u2014delayed or inaccurate identification of the causative pathogen can have serious consequences.<\/p>\n<p class=\"has-text-align-left\">\u201cIn respiratory care, time is everything. Knowing exactly what is making a patient sick allows clinicians to make fast, effective decisions that can save lives,\u201d says Josh Lauer, global head of molecular labs at Roche Diagnostics, in a release. \u201cWe are providing hospitals with a powerful tool to manage the complexity of respiratory infections, ensuring that patients\u2014especially those at high risk\u2014get the targeted care they need without delay.\u201d<\/p>\n<p>Panel Design and Target Coverage<\/p>\n<p class=\"has-text-align-left\">The cobas eplex RP3 panel runs on the <a class=\"text-editor-link-class\" href=\"https:\/\/clpmag.com\/diagnostic-technologies\/molecular-diagnostics\/molecular-diagnostic-analyzers\/roche-launches-updated-cobas-6800-8800-systems-enhanced-testing-capabilities\/\" rel=\"nofollow noopener\" target=\"_blank\">cobas<\/a> eplex system, a platform designed to simplify laboratory workflow through automated result reporting and external control tracking and monitoring. The panel builds on the target coverage of its predecessor, the RP2, retaining detection of common pathogens such as <a class=\"text-editor-link-class\" href=\"https:\/\/clpmag.com\/disease-states\/infectious-diseases\/flu-respiratory-infections\/fda-clears-four-plex-respiratory-test-covid-19-flu-a-b-rsv\/\" rel=\"nofollow noopener\" target=\"_blank\">influenza virus A and B, respiratory syncytial virus (RSV), and SARS-CoV-2<\/a>, while adding new targets including Bordetella parapertussis and Chlamydia pneumoniae \u2014 pathogens that can cause severe illness in high-risk patients, according to the company.<\/p>\n<p class=\"has-text-align-left\">The panel also features updated inclusivity for influenza virus and SARS-CoV-2 to ensure coverage of current and recently circulating strains, Roche says.<\/p>\n<p class=\"has-text-align-left\">A distinguishing feature of the RP3 panel is its flexible syndromic testing capability \u2014 the first in the cobas eplex product family. Laboratories can customize up to five distinct panels based on local prevalence patterns or unique patient presentations, according to Roche.<\/p>\n<p>Workflow and Clinical Utility<\/p>\n<p class=\"has-text-align-left\">The test requires less than one minute of hands-on time to initiate, according to the company. Roche says this ease of use, combined with fast time to results, can help reduce the time patients spend in the emergency department and allow hospitals to better manage isolation capacity.<\/p>\n<p class=\"has-text-align-left\">Beyond speed, the panel\u2019s broad target detection is designed to help clinicians identify the precise cause of infection more quickly\u2014enabling targeted treatment decisions, supporting appropriate infection and transmission control measures, and, in some cases, helping to reduce unnecessary antibiotic use, according to Roche.<\/p>\n<p class=\"has-text-align-left\">ID <a class=\"text-editor-link-class\" href=\"https:\/\/www.dreamstime.com\/image-virus-cells-floating-white-background-global-medicine-covid-pandemic-concept-digitally-generated-image375366329\" rel=\"nofollow noopener\" target=\"_blank\">375366329<\/a> \u00a9 <a class=\"text-editor-link-class\" href=\"https:\/\/www.dreamstime.com\/vectorfusionart_info\" rel=\"nofollow noopener\" target=\"_blank\">Wave Break Media Ltd<\/a> | <a class=\"text-editor-link-class\" href=\"http:\/\/Dreamstime.com\" rel=\"nofollow noopener\" target=\"_blank\">Dreamstime.com<\/a><\/p>\n<p class=\"has-text-align-left\">Related Reading:<\/p>\n<p class=\"has-text-align-left\">\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"Roche has launched the cobas eplex respiratory pathogen panel 3 (RP3), a qualitative in vitro diagnostic test capable&hellip;\n","protected":false},"author":2,"featured_media":38658,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[22506,3491,9023,3493,22507,22508,10146,22509,7016,22510,134,2057,22511,14147,22512,19512],"class_list":["post-38657","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-automated-laboratory-systems","tag-ce-mark","tag-clinical-laboratory","tag-in-vitro-diagnostics","tag-infectious-disease-testing","tag-influenza","tag-molecular-diagnostics","tag-multiplex-pcr","tag-respiratory-infections","tag-respiratory-pathogen-panel","tag-roche","tag-roche-diagnostics","tag-rsv","tag-sars-cov-2","tag-syndromic-testing","tag-workflow-automation"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116290596501912021","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/38657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=38657"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/38657\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/38658"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=38657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=38657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=38657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}